Education
About Us
Working with TipRanks
Follow Us
Kymera Therapeutics (KYMR)
NASDAQ:KYMR
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 47.07M | $ 78.59M | $ 46.83M | $ 72.83M | $ 34.03M |
| Gross Profit | $ 47.07M | $ 78.59M | $ 43.85M | $ 70.44M | $ -28.07M |
| Operating Income | $ -261.63M | $ -165.53M | $ -161.26M | $ -100.53M | $ -46.30M |
| EBITDA | $ -216.24M | $ -143.20M | $ -151.66M | $ -97.64M | $ -43.72M |
| Net Income | $ -223.86M | $ -146.96M | $ -151.83M | $ -98.00M | $ -43.95M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 488.74M | $ 374.88M | $ 559.49M | $ 567.61M | $ 458.73M |
| Total Assets | $ 978.03M | $ 575.76M | $ 603.13M | $ 605.90M | $ 487.18M |
| Total Debt | $ 87.76M | $ 84.67M | $ 17.34M | $ 17.96M | $ 17.99M |
| Net Debt | $ -32.49M | $ -25.29M | $ -51.06M | $ -30.01M | $ -13.01M |
| Total Liabilities | $ 142.42M | $ 180.79M | $ 112.98M | $ 146.27M | $ 203.29M |
| Stockholders' Equity | $ 835.62M | $ 394.97M | $ 490.15M | $ 459.64M | $ 283.89M |
| Cash Flow | |||||
| Free Cash Flow | $ -207.34M | $ -137.31M | $ -155.92M | $ -130.54M | $ 79.03M |
| Operating Cash Flow | $ -194.50M | $ -102.83M | $ -153.09M | $ -128.95M | $ 88.13M |
| Investing Cash Flow | $ -404.08M | $ 139.89M | $ 20.52M | $ -99.83M | $ -422.59M |
| Financing Cash Flow | $ 608.85M | $ 4.19M | $ 153.00M | $ 250.28M | $ 289.26M |